Bank of America
ENGNW icon

Bank of America’s enGene Therapeutics Warrants ENGNW Stock Holding History

Bank of America’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$798 – 6076
2025
Q4 		$798 Hold
300
– – ﹤0.01% 6493
2025
Q3 		$213 Hold
300
– – ﹤0.01% 7719
2025
Q2 		$246 Hold
300
– – ﹤0.01% 7805
2025
Q1 		$180 Buy
300
+100
+50% +$82 ﹤0.01% 7711
2024
Q4 		$169 Hold
200
– – ﹤0.01% 7625
2024
Q3 		$172 Hold
200
– – ﹤0.01% 7604
2024
Q2 		$238 Buy
+200
New +$640 ﹤0.01% 7522

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Bank of America's ENGNW Position: Q1 2026 in Review

Bank of America sold out of enGene Therapeutics Warrants (ENGNW) in Q1 2026, closing a stake of 300 shares — an estimated $798 sold.

Bank of America first reported a position in ENGNW in Q2 2024 and held it in 7 quarters. The position peaked at $798 in Q4 2025. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

  • Bank of America reported no remaining enGene Therapeutics Warrants position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 300 enGene Therapeutics Warrants shares in Q1 2026, an estimated $798.
  • Bank of America first reported a position in enGene Therapeutics Warrants in Q2 2024 and held it in 7 quarters.
  • Bank of America's enGene Therapeutics Warrants position peaked at $798 in Q4 2025.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.